Mycobacterium tuberculosis (Mtb) remains the main cause of mortality worldwide by bacterial infection. Cholesterol metabolism is essential for mycobacterial infection and long-term survival inside of host macrophages. Crucial for this pathway and Mtb survival inside of macrophages is 2-hydroxy-6-oxo-6-phenylhexa-2.4-dienoate hydrolase (HsaD) which catalyses the hydrolysis of carbon-carbon bonds via a serine protease-like catalytic triad [1] . The enzyme has a large active site cavity and readily forms crystals [2] . Its high thermal stability makes HsaD an ideal target for fragment-based drug discovery. To investigate novel inhibitors of HsaD a fragment library consisting of 1,258 compounds was screened via differential scanning fluorimetry (DSF) and hits were further checked by NMR. Inhibition efficiency of hits was characterized via a colorimetric assay using 2-hydroxy-6-oxo-6-phenylhexa-2.4-dienoic acid (HOPDA), an artificial, coloured substrate [1] . Two initial compounds referred to here as A and B were identified. A structureactivity relationship (SAR) study was performed using analogues of compounds A and B via DSF analysis and IC 50 determination by colorimetric assay. The crystal structures of HsaD with the best analogues of A and B are presented showing that the compounds interact with different areas of the active site cavity. The data collectively provide information for growing of each of these fragments to improve binding 
